CME Group Insider Filing: Suskind Receives $145k in Stock Compensation

Rhea-AI Filing Summary

Form 4 filing – CME Group Inc. (CME)

Director Dennis Suskind received 532 Class A common shares on 25 Jun 2025 under the CME Group Director Stock Plan. The grant price recorded for reporting purposes is $273.03 per share, implying a total market value of roughly $145 k. Following the award, Suskind’s direct beneficial ownership rose to 3,447 shares, an increase of about 18%. No open-market purchases, sales, or derivative transactions were reported, and there is no indication of a 10b5-1 trading plan. The transaction represents routine director compensation and does not materially affect CME’s share count or capital structure.

Positive

• Director ownership increases by 18%, marginally improving alignment between board and shareholders.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director stock grant; neutral market impact, modest alignment signal.

This Form 4 discloses a standard equity grant to director Dennis Suskind. The 532-share award, worth roughly $145 k, lifts his holdings to 3,447 shares. Because the shares were granted rather than purchased on the open market, the filing conveys limited incremental conviction about CME’s valuation. Nevertheless, higher insider ownership marginally tightens governance alignment. The amount is immaterial versus CME’s ~360 m shares outstanding, so the news should not influence valuation or liquidity. Overall, the filing is informational, with no material positive or negative signal for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Suskind Dennis

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2025		A(1)		532	A	$273.03	3,447	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Granted pursuant to the CME Group Director Stock Plan, as amended and restated.

Remarks:

	By: Jenelle Chalmers For: Dennis Suskind	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CME shares did Director Dennis Suskind acquire on 25-Jun-2025?

He received 532 Class A common shares through a stock plan grant.

What is Dennis Suskind’s total CME share ownership after the transaction?

His direct beneficial ownership stands at 3,447 shares.

Was the transaction an open-market buy or a stock grant?

It was a stock grant under the CME Group Director Stock Plan, not an open-market purchase.

What was the reported price per share for the grant?

The Form 4 lists a reference price of $273.03 per share.

Does the filing mention any derivative securities or a 10b5-1 plan?

No derivative transactions or 10b5-1 trading plans were disclosed.